These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8393388)

  • 1. Phase II study of 4'-iodo-4'-deoxydoxorubicin in non-resectable non-small-cell lung cancer.
    Sørensen JB; Stenbygaard L; Drivsholm L; Dombernowsky P; Hansen HH
    Cancer Chemother Pharmacol; 1993; 32(5):399-402. PubMed ID: 8393388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
    Bakker M; Droz JP; Hanauske AR; Verweij J; van Oosterom AT; Groen HJ; Pacciarini MA; Domenigoni L; van Weissenbruch F; Pianezzola E; de Vries EG
    Br J Cancer; 1998; 77(1):139-46. PubMed ID: 9459159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
    Rose C; Lad TE; Kilton LJ; Schor J; Rosen ST; Rossof AH; Blough RR; Johnson CM
    Invest New Drugs; 1990 Feb; 8(1):97-9. PubMed ID: 2160920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II studies of 4'-iodo-4'-deoxydoxorubicin in advanced non-small cell lung, colon and breast cancers.
    Sessa C; Calabresi F; Cavalli F; Cerny T; Liati P; Skovsgaard T; Sorio R; Kaye SB
    Ann Oncol; 1991; 2(10):727-31. PubMed ID: 1666296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4'-Deoxydoxorubicin, an inactive drug in small cell lung cancer.
    Giaccone G; Donadio M; Bonardi G; Bagatella M; Calciati A
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1407-8. PubMed ID: 2824210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of 4'-deoxydoxorubicin (DxDx) in non-small cell lung cancer: a Cancer and Leukemia Group B Trial.
    Ringenberg QS; Perry MC; Propert KJ; Modeas C; Hirsh V; Weiss RB; Richards F; Graziano S; Green M
    Med Pediatr Oncol; 1988; 16(1):27-9. PubMed ID: 2828901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.
    Gatzemeier U; Heckmayr M; Hossfeld DK; Zschaber R; Achterrath W; Lenaz L
    Cancer Chemother Pharmacol; 1990; 26(5):369-72. PubMed ID: 2170044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
    Smit EF; Piers DA; Postmus PE
    Eur J Cancer; 1992; 28A(12):1965-7. PubMed ID: 1329882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
    Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
    J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase-II clinical trial of 4'-epi-doxorubicin in advanced solid tumors.
    Martoni A; Giovannini M; Tomasi L; Camaggi CM; Bellanova B; Monetti N; Rossini G; Tarquinii M; Martini A; Pannuti F
    Cancer Chemother Pharmacol; 1984; 12(3):179-82. PubMed ID: 6584236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
    Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
    J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A randomized phase II trial of docetaxel and doxorubicin in treatment for patients with non-small-cell lung cancer who have failed previous platinum-based chemotherapy].
    Wang ZP; Sun Y; Zhang XR; Zhang MH; Wang XW; Yu XJ; Nan KJ; Li EX; Liu JW; Gao YJ; Guan XQ; Song SP; Sheng LJ; Wang DL; Wang ZX
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):465-8. PubMed ID: 19024525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
    Hainsworth JD; Thompson DS; Greco FA
    J Clin Oncol; 1995 Jul; 13(7):1609-14. PubMed ID: 7602349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society.
    Drings P; Günther IU; Gatzemeier U; Berdel W; Stahl M; Salewski E; Edler L
    Onkologie; 1990 Jun; 13(3):180-4. PubMed ID: 2168533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.